Turning complex radiochemistry into clinical reality.

This Hull Live article features work Dr Louis Allott has contributed towards in his fractional role of Director of Radiochemistry at the Molecular Imaging Research Centre, for the Daisy Appeal Charity.

“Aptamer Group plc announced the launch of a new targeted radiopharmaceutical programme in collaboration with Radiopharmium Ltd, a UK-based specialist consultancy in radiopharmaceutical development.”

This BBC News article features work Dr Louis Allott has contributed to for the Daisy Appeal through Radiopharmium Limited. This work reflects an ongoing contribution to the Daisy Appeal, providing strategic leadership in radiochemistry and clinical translation.

The programme is overseen by Dr Louis Allott, a member of Aptamer's Scientific Advisory Board and a recognised expert in the development and production of radiopharmaceuticals, with direct experience spanning laboratory discovery through to clinical translation.

Through his consultancy, Radiopharmium Ltd, Dr Allott takes a fractional role as Director of Radioligand Development for Aptamer, overseeing the radiochemical conjugation of Optimer® binders and their biological evaluation in established preclinical models, assessing safety, targeting performance and therapeutic potential prior to clinical trials.

Dr Louis Allott, Chief Executive Officer of Radiopharmium Ltd, commented: “I am delighted to be working with Aptamer, a recognised leader in the field of aptamer technology with a strong track record of success. The combination of Aptamer's innovative Optimer® platform and Radiopharmium's expertise in radiopharmaceutical development makes this collaboration well-positioned to demonstrate the potential of aptamer-based targeting in next-generation radiopharmaceuticals.”